Cytokines Effects on Learning and Memory

  • John M. Petitto
  • Martin J. Repetto
  • Zhi Huang
  • Ray D. BeckJr.
  • David A. Hartemink
Part of the Neurobiological Foundation of Aberrant Behaviors book series (NFAB, volume 7)


One of the earliest observations suggesting that cytokines could influence cognitive function in humans came from cancer studies where IL-2 immunotherapy was used to treat some types of neoplasias. Treatment with this pivotal immunoregulatory cytokine induced prominent, untoward neuropsychiatric side effects with patients exhibiting cognitive dysfunction (1,2). Seminal basic studies showed that peripheral immunization led to activation of hypothalamic neurons, and also demonstrated that lymphocytes had the capacity to produce neuropeptides (for reviews see 3,4). This sparked considerable growth in this area of research, and it is now well established that cytokines can communicate with endocrine and brain cells. Just as researchers were surprised several decades ago to discover that digestive peptides such as CCK and VIP were in the brain, cytokines and their receptors once believed to be derived solely from lymphoid cells have been identified in normal brain. They function as neuromodulators and neurotrophic factors, as well as mediators of immune-like responses involved in CNS pathology. As described in subsequent sections of the chapter, in the case of IL-2, a number of basic investigations have shown that this cytokine can modify various neurobiological processes associated with learning and memory.


Quantitative Trait Locus Spatial Learning Contextual Fear Conditioning Neurobiological Process Conditioning Quantitative Trait Locus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Denicoff, K.D., Rubinow, D.R., Papa, M.Z., et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Int. Med. 1987; 107: 293–300.PubMedGoogle Scholar
  2. 2.
    West, W.H., Tauer, K.W., Yannelli, J.R., et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. NEJM 1987; 316: 898–905.PubMedCrossRefGoogle Scholar
  3. 3.
    Besedovsky, H.O., del Rey, A., Klusman, I., et al. Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. J. Ster. Biochem. Mole. Biol. 1991; 40: 613–618.CrossRefGoogle Scholar
  4. 4.
    Blalock, J.E. The syntax of immune-neuroendocrine communications. Immunol. Today 1994;15:504–511.PubMedCrossRefGoogle Scholar
  5. 5.
    Pan, W. and Kastin, A.J. Penetration of neurotrophins and cytokines across the blood-brain/blood-spinal cord barrier. Adv. Drug Deliv. Rev. 1999; 36: 291–298PubMedCrossRefGoogle Scholar
  6. 6.
    Maier, S.F. and Watkins, L.R. Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood and cognition. Psychol Rev. 1998; 83–107Google Scholar
  7. 7.
    Petitto, J.M. and Huang, Z. Cloning the full-length IL-2/15 receptor-β cDNA sequence from mouse brain: evidence of enrichment in hippocampal formation neurons. Reg. Pep. 2001; 98: 77–87.CrossRefGoogle Scholar
  8. 8.
    Lapchak, P.A., Araujo, D.M., Quirion, R., et al. Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain. Neurosci. 1991; 44: 173–184..CrossRefGoogle Scholar
  9. 9.
    Petitto, J.M. and Huang, Z. Molecular cloning of a partial cDNA of the interleukin-2 receptor-β in normal mouse brain: in situ localization in the hippocampus and expression by neuroblastoma cells. Brain Res. 1994; 650: 140–145.PubMedCrossRefGoogle Scholar
  10. 10.
    Petitto, J.M., Huang, Z., Raizada, M., et al. Molecular cloning of the cDNA coding sequence of IL-2 receptor-γ (γc) from human and murine forebrain: expression in the hippocampus in situ and by brain cells in vitro. Mole. Brain Res. 1998; 53:152–62.CrossRefGoogle Scholar
  11. 11.
    Cunningham, E.T.J., Wada, E., Carter, D.B., et al. In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. J. Neurosci. 1992; 12: 1101–1114.PubMedGoogle Scholar
  12. 12.
    Licinio, J., Wong, M.L., and Gold, P.W. Localization of interleukin-1 receptor antagonist mRNA in rat brain. Endocrinology 1991; 129: 562–564.PubMedCrossRefGoogle Scholar
  13. 13.
    Schobitz, B., Voorhuis, D.A. and De Kloet, E.R. Localization of interleukin-6 mRNA and interleukin-6 receptor mRNA in rat brain. Neurosci. Lett. 1992; 136: 189–192.PubMedCrossRefGoogle Scholar
  14. 14.
    Laye, S., Parnet, P. Goujon, E., et al. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Brain research. Mole. Brain Res 1994; 27: 157–62.CrossRefGoogle Scholar
  15. 15.
    Pugh, C.R., Nguyen, K.T., Gonyea, J.L., et al. Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav. BrainRres. 1999; 106: 109–18.CrossRefGoogle Scholar
  16. 16.
    Gibertini, M., Newton, C., Klein, T.W., et al. Legionella pneumophila-induced visual learning impairment reversed by anti-interleukin-1 beta. Proceed. Soc. Exp. Biol. Med. 1995; 210:7–11.Google Scholar
  17. 17.
    Aubert, A., Vega, C., Dantzer, R., et al. Pyrogens specifically disrupt the acquisition of a task involving cognitive processing in the rat. Brain, Behav. Iimmun. 1995; 9: 129–48.CrossRefGoogle Scholar
  18. 18.
    Dantzer, R., Bluthe, R.M., Gheusi, G., et al. Molecular basis of sickness behavior. Ann. NY Acad. Sci. 1998; 856: 132–138.PubMedCrossRefGoogle Scholar
  19. 19.
    Bianchi, M., Sacerdote, P., Panerai, A.E. Cytokines and cognitive functions in mice. Biol. Signals. Recept. 1998; 7: 45–54.PubMedCrossRefGoogle Scholar
  20. 20.
    Capuron, L., Ravaud, A., Radat, F., et al. Effects of interleukin-2 and alpha interferon cytokine immunotherapy on the mood and cognitive performance of cancer patients. Neuroimmunomodul. 1998; 22: 9.Google Scholar
  21. 21.
    Nemni, R., lannaccone, S., Quattrini, A., et al. Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice. Brain Res. 1992;591:248–252.PubMedCrossRefGoogle Scholar
  22. 22.
    Bianchi, M. and Panerai, A.E. Interleukin-2 enhances scopolamine-induced amnesia and hyperactivity in the mouse. Neuroreport 1993; 4: 1046–1048.PubMedCrossRefGoogle Scholar
  23. 23.
    Hanisch, U., Neuhaus, J., Rowe, W., et al. Neurotoxic consequences of central long-term administration of interleukin-2 in rats. Neurosci. 1997; 79: 799–818.CrossRefGoogle Scholar
  24. 24.
    Lacosta, S., Merali, Z., Animan, H. Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors and anxiety. Behav. Neurosci. 1999; 113: 1030–1041.PubMedCrossRefGoogle Scholar
  25. 25.
    Reichemberg, A., Yirmiya, R., Schuld, A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiat. 2001; 58:445–452.CrossRefGoogle Scholar
  26. 26.
    Maren, S., De Oca, B. and Fanselow, M.S. Sex differences in hippocampal long-term potentiation (LTP) and Pavlovian fear conditioning in rats: positive correlation between LTP and contextual learning. Brain Research 1994; 24: 66: 25–34.CrossRefGoogle Scholar
  27. 27.
    Morris, R.G.M. Synaptic plasticity and learning: selective impairment of learning in rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor anatagonist AP5. J. Neurosci. 1989; 9: 3040–3057.PubMedGoogle Scholar
  28. 28.
    Jankowsky, J., Patterson, P. Cytokine and growth factor involvement in long-term potentiation. Mole. Cell. Neurosci. 1999; 14:273–286.Google Scholar
  29. 29.
    Schneider, H., Pitossi, F., Balschun, D., et al. A neuromodulatory role of interleukine-lb in the hippocampus. Proceed. Natl. Acad. Sci. USA 1998; 95:7778–7783.CrossRefGoogle Scholar
  30. 30.
    Jankowsky, J.L., Derrick, B.E., Patterson, P.H. Cytokine responses to LTP induction in the rat hippocampus: a comparison of in vitro and in vivo techniques. Learning & Memory 2000; 7: 400–12.CrossRefGoogle Scholar
  31. 31.
    Bellinger, F.P., Madamba, S.G., Campbell, I.L., et al. Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci. Lett. 1995; 198: 95–8.\PubMedCrossRefGoogle Scholar
  32. 32.
    Li, A., Katafuchi, T., Oda, S., et al. Interleukin-6 inhibits long term potentiation in rat hippocampal slices. Brain Res. 1997; 748:30–38.PubMedCrossRefGoogle Scholar
  33. 33.
    Tancredi, V., Zona, C., Velotti, F., et al. Interleukin-2 suppresses established long-term potentiation and inhibits its induction in the rat hippocampus. Brain Res. 1990; 525:149–151.PubMedCrossRefGoogle Scholar
  34. 34.
    Tancredi, V., D’Archangelo, G., Grassi, F., et al. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci. Lett. 1992; 146:176–178.PubMedCrossRefGoogle Scholar
  35. 35.
    Cunningham, A.J., Murray, C.A., O’Neil, L.A., et al. Interleukin-1β (IL-1β) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci. Lett. 1996; 203:17–20.PubMedCrossRefGoogle Scholar
  36. 36.
    Katsuki, H., Nakai, S., Hirai, Y., et al. Interleukin-1β inhibits long-term potentiation in the CA3 region of mouse hippocampal slices. Eur. J. Pharmacol 1990; 181:323–326.PubMedCrossRefGoogle Scholar
  37. 37.
    Dantzer, R., Aubert, A., Bluthe, R.M., et al. Mechanisms of the behavioural effects of cytokines. Adv. Exp. Med. Biol. 1999; 461:83–105.PubMedCrossRefGoogle Scholar
  38. 38.
    Ader, R., Felten, D., Cohen, N. (Eds.) Psychoneuroimmunology, 3rd Edition, Academic Press, San Diego, CA, 2001.Google Scholar
  39. 39.
    Plata-Salaman, C.R., Ffrench-Mullen, S.M. Interleukin-2 modulates calcium currents in dissociated hippocampal CA1 neurons. Neuroreport. 1993; 4: 579–581.PubMedCrossRefGoogle Scholar
  40. 40.
    .Hanisch, U.K., Seto, D., and Quirion, R. Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2. J. Neurosci. 1993; 13(8): 3368–3374.PubMedGoogle Scholar
  41. 41.
    Hanisch, U.K., Seto, D., Quirion, R. Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2. J. Neurosci. 1993; 12: 3368–3374.Google Scholar
  42. 42.
    Seto, D., Satyabrata, K. and Quirion, R. Evidence for direct and indirect mechanisms in the potent modulatory action of interleukin-2 on the release of acetylcholine in rat hippocampal slices. Brit. J. Pharmcol.y 1997; 120: 1151–1157.CrossRefGoogle Scholar
  43. 43.
    Hanisch, U.K. and Quirion R. Interleukin-2 as a neuroculatory cytokine. Brain Res. Rev. 1996;21:246–284.CrossRefGoogle Scholar
  44. 43.
    Araujo, D.M., Lapchak, P.A. Induction of immune system mediators in the hippocampal formation in Alzheimer’s and Parkinson’s diseases: Selective effects on specific interleukin receptors. Neuroscience 1994; 61: 745–754.PubMedCrossRefGoogle Scholar
  45. 44.
    Campbell, I.L., Krucker, T., Steffensen, S., et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res. 1999; 835:46–61.PubMedCrossRefGoogle Scholar
  46. 45.
    Araujo, D.M., Lapchak, P.A., Collier, B., et al. Interleukin-2 interacts with opioid neuroculatory systems in the rat hippocampus. Prog. Clin. Biol. Res. 1990; 328: 355–358.PubMedGoogle Scholar
  47. 46.
    Awatsuji, H., Furukawa, Y., Nakajima, M., et al. Interleukin-2 as a neurotrophic factor for supporting the survival of neurons cultured from various regions of fetal rat brain. J. Neurosci. Res. 1993; 35: 305–311.PubMedCrossRefGoogle Scholar
  48. 47.
    Sarder, M., Saito, H. and Abe, K. Interleukin-2 promotes survival and neurite extension of cultured neurons from fetal rat brain. Brain Res. 1993; 625: 347–350.PubMedCrossRefGoogle Scholar
  49. 48.
    Sarder, M., Abe, K., Saito, H., et al. Comparative effect of IL-2 and IL-6 on morphology of cultured hippocampal neurons from fetal rat brain. Brain Res. 1996; 715: 9–16.PubMedCrossRefGoogle Scholar
  50. 49.
    Mennicken, F. and Quirion, R. Interleukin-2 increases choline acetyltransferase activity in septal-cell cultures. Synapse 1997; 26: 175–183.PubMedCrossRefGoogle Scholar
  51. 50.
    Petitto, S.M., McNamara, R., Gendreau, P.L. et al. Impaired learning and memory and altered hippocampal neurodevelopment resulting from IL-2 gene deletion. J. Neurosci Res. 1999; 56: 441–446.PubMedCrossRefGoogle Scholar
  52. 51.
    Kadotani, H., Faraco, J. and Mignot E. Genetic studies in the sleep disorder narcolepsy. Genome Res. 1998;8:427–34.PubMedGoogle Scholar
  53. 52.
    Petitto, J.M. “Behavioral genetics and immunity”. In Psychoneuroimmunology, Third Edition. Ader, Felten and Cohen eds. San Diego, CA: Academic Press, 2001, pp. 173–186.Google Scholar
  54. 53.
    Hickey, W.F., Hsu, B.L., and Kimura, H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 1991; 28: 254–260.PubMedCrossRefGoogle Scholar
  55. 54.
    McAllister, C.G., van-Kammen, D.P., Rehn, T.J., et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiat. 1995; 152: 1291–1297.PubMedGoogle Scholar
  56. 55.
    Ganguli, R., Brar, J.S., Chengappa, K.N., et al. Autoimmunity in schizophrenia: a review of recent findings. Ann. Med. 1993; 25:489–496.PubMedCrossRefGoogle Scholar
  57. 56.
    Nishiyama, N. Thymectomy-induced deterioration of learning and memory. Cell. Mole. Biol. 2001;47:161–165.Google Scholar
  58. 57.
    Carrie, A., Jun, L., Bienvenu, T., et al. A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nature Genetics 1999; 23: 25–31.PubMedGoogle Scholar
  59. 58.
    Kolsch, H., Ptok, U., Bagli, M, et al. Gene polymorphisms of interleukin-1 alpha influence the course of Alzheimer’s disease. Ann.Neurol. 2001; 49: 818–9PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • John M. Petitto
    • 1
  • Martin J. Repetto
    • 1
  • Zhi Huang
    • 1
  • Ray D. BeckJr.
    • 1
  • David A. Hartemink
    • 1
  1. 1.McKnight Brain InstituteUniversity of Florida, College of MedicineGainesvilleUSA

Personalised recommendations